Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn’s disease

References

• Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for crohn’s disease: results of the ICC registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020;14(1):33–45.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Verstockt B, Gils A, Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group], et al. Long-term clinical effectiveness of ustekinumab in patients with crohn’s disease who failed biologic therapies: a national cohort study. J Crohn’s Colitis. 2019;13(11):1401–1409.
   Google Scholar
• Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in crohn’s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13(7):864–872.
   PubMed Web of Science ®Google Scholar
• Rubín de Célix C, Chaparro M, Gisbert JP. Real-World evidence of the effectiveness and safety of ustekinumab for the treatment of crohn’s disease: systematic review and Meta-Analysis of observational studies. J Clin Med. 2022;11(14):4202.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232–1243.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-Target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(5):1275–1285 e2.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–2224.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Zou G, Garg SK, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and Meta-Analysis. Am J Gastroenterol. 2015;110(6):802–819. quiz 20.
   PubMed Web of Science ®Google Scholar
• Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978–1988.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of crohn’s-disease activity. Lancet. 1980;1(8167):514.
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262–267.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–169.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332–341.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14(1):40–46.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Oortwijn A, Rijnders N, et al. P317 characterisation of patients with delayed response to ustekinumab for crohn’s disease. J Crohn Colitis. 2019;13(Supplement_1):S259–S260.
   PubMed Web of Science ®Google Scholar
• Simon EG, Ghosh S, Iacucci M, et al. Ustekinumab for the treatment of crohn’s disease: can it find its niche? Therap Adv Gastroenterol. 2016;9(1):26–36.
   PubMed Web of Science ®Google Scholar
• Narula N, Wong ECL, Dulai PS, et al. Week 6 calprotectin best predicts likelihood of long-term endoscopic healing in crohn’s disease: a post-hoc analysis of the UNITI/IM-UNITI trials. J Crohns Colitis. 2021;15(3):462–470.
   PubMed Web of Science ®Google Scholar
• Fumery M, Peyrin-Biroulet L, Nancey S, et al. Effectiveness and safety of ustekinumab intensification at 90 mg every 4 weeks in crohn’s disease: a multicentre study. J Crohn Colitis. 2021;15(2):222–227.
   Web of Science ®Google Scholar
• Storan D, Doherty GA, Cullen G. Ustekinumab 90 mg every 2 weeks for the treatment of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2021;19(7):1502.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–255.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Cuomo A, et al. Real-life efficacy and safety of ustekinumab as second- or third-line therapy in crohn’s disease: results from a large italian cohort study. Eur Rev Med Pharmacol Sci. 2021;25(4):2099–2108.
   PubMed Web of Science ®Google Scholar